SBRT for Extra-cranial Oligorecurrent Tumor

Status Not yet recruiting

Clinical Trial Summary

Clinical experience has shown that metastasis can often be limited in number and location, and thus amenable to local treatment. The term oligometastasis describes an intermediate state of cancer spread between localized disease and widespread metastasis. The implication of such an intermediate state is that the disease can be cured by using metastasis-directed therapy. Historically, in some patients with oligometastases in the liver or lungs, surgical resection was often indicated, as abundant evidence suggested it could improve progression-free or overall survival. Recently, several studies have reported promising outcomes of >80% local control with Stereotactic Body Radiotherapy (SBRT) in patients with lung or liver oligometastases. Nonetheless, very few studies have focused on non-liver, non-lung extracranial oligometastatic lesions treated with SBRT, and such studies have limitations of a retrospective nature and small sample sizes.Because allmost studies are based on single-arm studies without appropriate controls, the level of evidence to support SBRT is weak. Randomized trials are therefore necessary to establish the utility of SBRT for oligometastatic disease.

This study is designed as a randomized phase II study. Patients will be randomized between current standard treatment (Arm 1) versus standard treatment +SBRT (Arm 2) to all known disease.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02410187
Study type	Interventional
Source	Korea Cancer Center Hospital
Contact	Mi-Sook Kim, M.D. Ph.D.
Phone	+82-2-970-1264
Email	mskim@kirams.re.kr
Status	Not yet recruiting
Phase	Phase 2
Start date	March 2016
Completion date	March 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05045040` - Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions	N/A
Recruiting	`NCT05415475` - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors	Phase 1
Completed	`NCT04596865` - Recurrence After Whipple's (RAW) Study
Recruiting	`NCT06103617` - Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer	Phase 2
Completed	`NCT05364905` - Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma
Recruiting	`NCT05396300` - A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors	Phase 1
Completed	`NCT03441100` - TCR-engineered T Cells in Solid Tumors: IMA202-101	Phase 1
Recruiting	`NCT05359445` - IMA401 TCER® in Recurrent and/or Refractory Solid Tumors	Phase 1
Recruiting	`NCT03686124` - ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors	Phase 1
Not yet recruiting	`NCT04889742` - Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors	Phase 2
Recruiting	`NCT05189054` - Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors
Completed	`NCT03132038` - Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck	Phase 2
Not yet recruiting	`NCT06208657` - Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer	Phase 1/Phase 2
Not yet recruiting	`NCT04784221` - Nanoparticles and Hypofractionated Protontherapy for Reirradiation of Pantumor Relapse	Phase 2
Recruiting	`NCT05855811` - PREventing Second Cancers With DOSTARlimab	Phase 2
Recruiting	`NCT05626829` - Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma	Phase 2
Completed	`NCT03941262` - Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy	Phase 1
Not yet recruiting	`NCT06372574` - A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors	Phase 1
Completed	`NCT05200195` - Deep Learning Model for the Prediction of Post-LT HCC Recurrence
Completed	`NCT03760952` - Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling